M

Morphotek

Biotech & Life Sciences · United States · Founded 1999

Morphotek, Inc. operates as a clinical-stage biopharmaceutical company, focusing on the development of therapeutic monoclonal antibodies for treating cancer, inflammatory conditions, and infectious diseases. Founded in May 2000 by Drs. Nicholas Nicolaides, Luigi Grasso, and Phillip Sass, the company originated from technology developed at Johns Hopkins University. Dr. Nicolaides' research into the genetic cause of a common inherited cancer led to the creation of Morphotek's foundational morphogenics technology, a whole genome evolution platform. The company's business is centered on discovering and developing protein and antibody products. Morphotek leverages proprietary human antibody technologies, such as Human MORPHODOMA® and Libradoma™, to build its product pipeline. This technology is designed to yield genetically diverse cell lines suitable for pharmaceutical development. A significant milestone was the company's acquisition by Eisai Co., Ltd. in April 2007 for $325 million, after which it continued to operate as a subsidiary under its existing management. Following the acquisition, Morphotek became Eisai's central biologics development division, expanding the parent company's capabilities from small-molecule drugs into the biologics field. Morphotek's product development pipeline has included several clinical-stage monoclonal antibodies. At the time of its acquisition, it had two programs in early-stage clinical trials: MORAb-003 for ovarian cancer and MORAb-009 for pancreatic cancer. The company's portfolio targets various diseases, including rheumatoid arthritis and infectious diseases, in addition to its primary focus on oncology. In 2017, Morphotek launched an Antibody Drug Conjugate (ADC) Services business. This service provides third-party clients with access to its proprietary eribulin-linker payload and REsidue-SPEcific Conjugation Technology™ (RESPECT™), allowing for the development of homogeneous ADCs with defined drug-to-antibody ratios. This end-to-end service includes options from antibody development to GMP manufacturing and the creation of companion diagnostics. Keywords: monoclonal antibodies, biopharmaceutical, oncology, cancer treatment, antibody drug conjugate, Eisai subsidiary, inflammatory diseases, infectious diseases, Human MORPHODOMA, Libradoma, antibody engineering, clinical-stage, drug discovery, biologics development, morphogenics, Nicholas Nicolaides, Luigi Grasso, protein therapeutics, ADC services, RESPECT technology, eribulin